<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>After briefly evaluating the contraindications and indications of vasoactive and eumetabolic therapy of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, the paper considers the main drugs at present in use in therapy of the syndrome induced by diffused cerebral <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Among the drugs with a mainly vasoactive effect, consideration is given in particular to <z:chebi fb="1" ids="7565">nifedipine</z:chebi>, cetiedil and nicergoline, which induced not only an improvement in the subjective symptoms, but also an increase--which was notable at times--in the sphygmic amplitude of the rheoencephalogram </plain></SENT>
<SENT sid="2" pm="."><plain>Where drugs with a mainly eumetabolic action are concerned, xanthinol <z:chebi fb="2" ids="32544">nicotinate</z:chebi>, <z:chebi fb="0" ids="9985">vincamine</z:chebi> and (-)eburnamonine are discussed </plain></SENT>
<SENT sid="3" pm="."><plain>The latter, in particular, proved effective in improving intellective recovery and mediate and deferred memory, accompanied by a fair increase in the sphygmic speed and amplitude on the rheoencephalogram </plain></SENT>
</text></document>